CMPX · Compass Therapeutics Inc
United States · RS rating 2 · As of 2026-10-14
| Price | 0.88 USD |
|---|---|
| 1-day change | +2.6% |
| RS rating (overall / 1M / 3M / 12M) | 2 / 2 / 4 / 6 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 24 / 3 / 24 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | -12.5% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +86.9% |
| Market cap (USD) | $938.3M |